最新資訊

11月 21日, 2019

新旭生技今日宣布其18F-APN-1607 tau蛋白正子攝影 (PET) 示蹤劑已在美國啟動多國多中心的臨床二期試驗。本試驗 (NCT04141150) 將比較「因阿茲海默症而引發的輕度認知功能障礙患者」、「阿茲海默症的失智症患者」與「老年健康受試者」大腦內tau蛋白堆積程度的差異。

08月 30日, 2019
新旭生技與日本慶應義塾大學(Keio University)簽署合作合約
新旭生技與日本慶應義塾大學(Keio University)簽署合作合約,授權慶應大學使用新旭tau PET影像示蹤劑 18F-APN-1607 (PM-PBB3),屆而將失智症病人分類。此次合作為慶應大學與衛采製藥(Eisai Co., Ltd.)共同創新實驗室執行研究計畫中的一部分(Eisai-Keio Innovation Laboratory for Dementia, EKID),並由日本醫學研究和發展局(Japan Agency for Medical Research and Development, AMED)的研究經費補助 (計畫編號: JP17pc0101006)。新旭生技非常感謝能為此研究計畫貢獻,進而更深入了解失智症,尤其是阿茲海默症。
07月 01日, 2019

05月 23日, 2019

新旭生技於今日宣佈近期獲得美國Michael J. Fox 帕金森氏症研究基金會 (The Michael J. Fox Foundation for Parkinson's Research, MJFF) 的研究經費獎項,所獲資金將用於公司目前所開發中的alpha-synuclein蛋白正子造影示蹤劑 (alpha-synuclein PET tracer)。

03月 26日, 2019

新旭生技獲《數位時代》媒體與科技部合作2019年度台灣「最酷科技新創」評選。從122家符合資格的科技新創公司中,脫穎而出位列前十。 經編輯團隊研究、整理相關基本資料後,共有 122 家新創團隊符合前述資格,由《數位時代》所邀請領域專家就技術能量、國際市場發展潛力、產業影響力與團隊發展潛能等四面向進行線上評分,以序分法評選出領域專家共同認定最具潛力的20家新創企業,再經由專家諮詢會議討論,評選出「2019年台灣最創新的10家科技類新創」。 以下是數位時代報導全文:

12月 25日, 2018

APRINOIA Therapeutics, a clinical-stage biotechnology company developing therapeutics and diagnostic imaging tools for neurodegenerative diseases, announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [  F]-labeled positron emission tomography (PET) imaging tracer, to suppo...

09月 01日, 2018
APRINOIA Will Participate Asia-China: 2018 Clinical Trials on Alzheimer’s Disease Conference
APRINOIA will sponsor the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.
01月 16日, 2018

APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (T...